Cite
HARVARD Citation
Bartoletti, M. et al. (n.d.). EP795 Searching for the best maintenance therapy in platinum-sensitive recurrent ovarian cancer: bevacizumab or PARP-inhibitors? A network meta-analysis. International journal of gynecological cancer. pp. A437-A438. [Online].